In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Allergy Therapeutics today said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary goal, with the news sending the UK biotech’s shares up 20.8% to 1.80 pence. 14 November 2023
Pharmaceutical
German drugmaker Boehringer Ingelheim has inked a deal with China’s ChromX Health, aimed at researching ways to improve treatment outcomes for people with interstitial lung diseases. 14 November 2023
Pharmaceutical
Spanish dermatology specialist Almirall and US generative AI drug creation company Absci Corporation have announced a drug discovery partnership. 14 November 2023
Pharmaceutical
Aclaris Therapeutics stock has taken a battering again, after the Phase IIb ATI-450-RA-202 trial was found to have missed its primary and secondary endpoints. 14 November 2023
Biotechnology
UK pharma major AstraZeneca today announced two developments for its best-selling cancer drug Imfinzi (durvalumab). 14 November 2023
Pharmaceutical
Boston, USA-based PureTech Health saw its London-listed share edge up 1.6% to 176.00 pence, after it announced top-line results from its Phase IIa, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone) in anxiety. 14 November 2023
Biotechnology
Japan’s Ajinomoto is moving further into the pharma sector with its proposed acquisition of US biotech firm Forge Biologics. 14 November 2023
Biotechnology
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
Biotechnology
Legend Biotech Corporation has entered into an exclusive, global license agreement with Swiss pharma giant Novartis. 13 November 2023
Pharmaceutical
Israel-headquartered Teva Pharmaceutical Industries has entered a collaboration with Royalty Pharma to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749). 13 November 2023
Pharmaceutical
Liver disease specialist Terns Pharmaceuticals has announced top-line data from the Phase IIa DUET trial at the American Association for the Study of Liver Diseases (AASLD). 13 November 2023
Biotechnology
Dutch biotech company VectorY Therapeutics today announced the close of a 129 million-euro ($138 million) Series A financing. 13 November 2023
Biotechnology
Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. 13 November 2023
Biotechnology
US neuroscience-focused biopharma Neurocrine Biosciences today announced that it has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of Ingrezza (valbenazine) prior to the expiration of applicable Neurocrine patents. 13 November 2023
Biotechnology
Canadian biotech Zymeworks has reacquired rights for the antibody-drug conjugate (ADC) zanidatamab zovodotin, from partner BeiGene. 13 November 2023
Pharmaceutical
UK-based Kelso Pharma today revealed it has taken its first step in its European expansion strategy by agreeing to acquire Italy’s Velit Biopharma which, like Kelso is a specialty pharma company. 13 November 2023
Pharmaceutical
In a strongly-worded statement, the Hellenic Association of Pharmaceutical Companies (SFEE) has argued against mandatory rebates on drug expenditure. 13 November 2023
Biotechnology
Following US approval in the same indication earlier this year, Japanese drugmaker Daiichi Sankyo’s Vanflyta (quizartinib) has now also been approved in the European Union (EU). 13 November 2023
Pharmaceutical
US clinical-stage liver disease specialist Madrigal Pharmaceuticals’ shares gained 1.8% to $138.84 on Friday, as it announced new data from the Phase III MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom. 13 November 2023
Biotechnology
US neurology specialist Neurocrine Biosciences saw its shares fall 4.4% to $107.17 after it announced negative Phase II study results from two signal-seeking pipeline programs in focal onset seizures and anhedonia. 13 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze